Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.
|Headquarters||333 Lakeside Drive|
FOSTER CITY, CA, United States 94404
|Chairman of the Board, Chief Executive Officer||John Martin|
|President, Chief Operating Officer||John Milligan|
|Chief Financial Officer, Senior Vice President||Robin Washington|
|Executive Vice President - Research and Development, Chief Scientific Officer||Norbert Bischofberger|
|Executive Vice President - Corporate and Medical Affairs||Gregg Alton|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||1.5B||Book Value||$6.13|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||8.6|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||27.1x|
|Pay Date||1/1/01||Operating Margin||42.63%|
*GAAP = prior to non-GAAP analyst adjusted earnings.